The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial.
NGS
acute
azacytidine
clinical trials and observations
complete remission
cytarabine
genetic risk
leukemia
leukemic cells
myelocytic
myeloid neoplasia
older adults
prognostic factors
variants
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
18 May 2021
18 May 2021
Historique:
received:
14
04
2021
revised:
06
05
2021
accepted:
12
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
We sought to predict treatment responses and outcomes in older patients with newly diagnosed acute myeloid leukemia (AML) from our FLUGAZA phase III clinical trial (PETHEMA group) based on mutational status, comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA). Mutational profiling using a custom 43-gene next-generation sequencing panel revealed differences in profiles between older and younger patients, and several prognostic markers that were useful in young patients were ineffective in older patients. We examined the associations between variables and overall responses at the end of the third cycle. Patients with mutated
Identifiants
pubmed: 34070172
pii: cancers13102458
doi: 10.3390/cancers13102458
pmc: PMC8158477
pii:
doi:
Banques de données
ClinicalTrials.gov
['NCT02319135']
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Instituto de Salud Carlos III
ID : PI16/01530, PI16/01661, PI19/01518 and PI19/00730, CIBERONC; CB16/12/00369
Organisme : CRIS against Cancer foundation
ID : grant 2018/001
Références
Cancer Discov. 2019 Aug;9(8):1050-1063
pubmed: 31088841
Nat Commun. 2019 Jan 16;10(1):244
pubmed: 30651561
Haematologica. 2020 Jul 30;:
pubmed: 32732356
Cancer. 2021 Jun 15;127(12):2003-2014
pubmed: 33626197
Blood. 2009 Apr 30;113(18):4179-87
pubmed: 19008455
Leukemia. 2018 Dec;32(12):2546-2557
pubmed: 30275526
Oncotarget. 2016 Aug 23;7(34):55264-55275
pubmed: 27419369
Blood. 2019 Jan 3;133(1):7-17
pubmed: 30361262
Ann Hematol. 2020 Mar;99(3):501-511
pubmed: 31965269
Blood Cancer J. 2021 Feb 22;11(2):41
pubmed: 33619261
Cancer. 2007 Mar 15;109(6):1114-24
pubmed: 17315155
Genes Chromosomes Cancer. 2018 Aug;57(8):401-408
pubmed: 29663558
Leukemia. 2011 Jul;25(7):1147-52
pubmed: 21494260
Blood. 2014 Oct 23;124(17):2705-12
pubmed: 25224413
N Engl J Med. 2016 Nov 24;375(21):2023-2036
pubmed: 27959731
Blood Adv. 2019 Jun 25;3(12):1837-1847
pubmed: 31208955
J Clin Oncol. 2010 Feb 1;28(4):562-9
pubmed: 20026804
Haematologica. 2019 Feb;104(2):288-296
pubmed: 30093399
Oncotarget. 2018 Jun 12;9(45):27882-27894
pubmed: 29963245
Cancers (Basel). 2018 Jun 26;10(7):
pubmed: 29949858
Blood. 2017 Jan 26;129(4):424-447
pubmed: 27895058
Br J Haematol. 2020 May;189(4):672-683
pubmed: 32068246
Blood. 2017 Aug 10;130(6):732-741
pubmed: 28588019
J Clin Oncol. 2008 Oct 1;26(28):4603-9
pubmed: 18559876
Blood Adv. 2021 Feb 9;5(3):760-770
pubmed: 33560390